Aurobindo Pharma Limited announced that its wholly-owned subsidiary, CuraTeQ Biologics Private Limited, has mutually agreed to terminate its license agreement with BioFactura Inc, USA. The agreement, originally entered into on July 7, 2023, was for the commercialization of BFI-751, a proposed biosimilar to Stelara (Ustekinumab). The termination, effective December 27, 2025, is attributed to CuraTeQ's strategic portfolio prioritization. The company stated that this decision is not expected to have a material impact on Aurobindo Pharma's overall biosimilars strategy. The original agreement included a profit-sharing arrangement, global manufacturing rights for CuraTeQ, and license fees spread across different milestones for BioFactura.